ClinicalTrials.Veeva

Find clinical trials for Lymphoma in Berlin, BE

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Berlin, BE, DEU:

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. (MAGNIFY)

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Celgene
Celgene

Berlin, Germany and 125 other locations

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3

Novartis
Novartis

Berlin, Germany and 66 other locations

with Refractory/Relapsing (R/R) KIR3DL2 positive Peripheral T Cell Lymphoma (PTCL) : Not Other Specified (NOS), PTCL-TFH (including Angioimm...

Enrolling
Peripheral T Cell Lymphoma
Relapse/Recurrence
Drug: Lacutamab
Drug: Oxaliplatine

Phase 2

The Lymphoma Academic Research Organisation

Berlin, Germany and 63 other locations

The goal of this clinical trial is to study the addition of Acalabrutinib to standard R-miniCHOP in older adults with DLBCL. The main question it aim...

Enrolling
Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma
Drug: R-miniCHOP + Acalabrutinib
Drug: R-miniCHOP

Phase 3

Universität des Saarlandes

Berlin, Germany and 16 other locations

and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Hodgkin Disease
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Berlin, Germany and 73 other locations

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoc...

Active, not recruiting
Mantle-Cell Lymphoma
Drug: Ibrutinib
Drug: Venetoclax

Phase 3

Pharmacyclics
Pharmacyclics

Berlin, Germany and 119 other locations

Combined modality approach using Obitunuzumab and involved site low dose irradiation in early stage nodal follicular lymphoma. Radiation dos...

Active, not recruiting
Stage II Grade 2 Follicular Lymphoma
Stage I Follicular Lymphoma Grade 1
Drug: Obinutuzumab Injection [Gazyva]
Radiation: Low dose radiation Therapy (LDRT)

Phase 2

Heidelberg University

Marburg, Germany and 11 other locations

or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and ...

Active, not recruiting
Lymphoma
Drug: Rituximab
Drug: CC-220

Phase 1

Celgene
Celgene

Berlin, Germany and 25 other locations

safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma...

Active, not recruiting
Mantle Cell Lymphoma
Drug: Rituximab
Drug: Bendamustine

Phase 3

Janssen (J&J Innovative Medicine)

Berlin, Germany and 203 other locations

The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritama...

Active, not recruiting
Small Lymphocytic Lymphoma (SLL)
Marginal Zone Lymphoma (MZL)
Biological: Epcoritamab

Phase 1, Phase 2

Genmab
Genmab

Berlin, Germany and 84 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems